Evidence suggests that extracellular TG2 plays a role in tumour progression by means of its transamidation activity, and therefore, the MDA-MB-231 tumour model appears suitable for evaluation of TG2 PET tracers in vivo, which is supported by the imaging results using [18F]2. The gene discussed is TGM2; the disease is neoplasm.